Loading...

CYTM

GDTC

CYTOMED THERAPEUTICS LTD

(GDTC)

2025 6-K

Show Summary

Summary

Company Expansion

ATM Offering Program

Clinical Trial Update

Share Issuance Approval

Annual Meeting Results

Annual Meeting Notice

Financial Results Update

Collaboration Agreement

Leadership Changes

First Patient Dosed

Clinical Trial Funding

Asset Acquisition

Financial Report Update

Board Restructure

Board Resignation

Annual Shareholders Meeting

Proxy Statement Update

Annual Meeting Notice

Shareholder Cell Banking

Research Partnership

External Links:

On June 26, 2025, CytoMed Therapeutics held its annual shareholders meeting with 66.06% of outstanding shares represented; key approvals included financial statements for 2024 and payment of directors' fees totaling $70,000.

AI Assistant

CYTOMED THERAPEUTICS LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.